Loading company…
French biopharmaceutical company developing personalized T-cell immunotherapies for cancer and autoimmune diseases.
Founded in 2001 in France, TxCell S.A. develops personalized immunotherapies, mainly T-cell therapies for cancer and autoimmune disorders, for hospitals and biopharmaceutical companies. CEO Damian Marron leads the company, which has completed 7 deals. Its most recent round was EUR 1.2 mn of Venture Debt led by Bpifrance on April 14, 2014. The company has raised EUR 16.2 mn in total, including an IPO in which it sold 2.9 million shares at EUR 5.58. It is listed at the Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in